
CLL Frontline Triplets and BTK Inhibitor Choice at Relapse
The panelists discussed triplet regimens combining a Bruton tyrosine kinase (BTK) inhibitor, venetoclax, and obinutuzumab for chronic lymphocytic leukemia (CLL), noting higher rates of undetectable measurable residual disease than with doublets.
Episodes in this series

The panelists discussed triplet regimens combining a Bruton tyrosine kinase (BTK) inhibitor, venetoclax, and obinutuzumab for chronic lymphocytic leukemia (CLL), noting higher rates of undetectable measurable residual disease than with doublets. They described acalabrutinib, pirtobrutinib, and zanubrutinib triplet approaches and apparent progression-free survival gains in patients with unmutated immunoglobulin heavy chain variable genes. They cautioned that more myelosuppression, infections, and infusion reactions warrant a discussion of risks and benefits and suggested that triplets may best suit younger patients with unmutated disease. The panelists then discussed relapsed/refractory disease, reviewing the randomized trials that inform BTK inhibitor selection. They considered switching between covalent agents appropriate for intolerance, not progression. They also discussed the expanded role of pirtobrutinib after any covalent BTK inhibitor and described monotherapy as reasonable when venetoclax is a poor fit, while noting that supporting data in this earlier setting come from a small group of patients.
Related to this article







